RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
Completed
1 enrolled
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Completed
1,149 enrolled
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
Phase 1/2 Completed
1,080 enrolled 28 charts
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
Phase NA Completed
65 enrolled 10 charts
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Completed
1,149 enrolled
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Completed
4,626 enrolled
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Completed
361 enrolled
CHARMS
Phase NA Completed
82 enrolled 20 charts
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Phase 3 Completed
676 enrolled 15 charts
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Phase 2 Completed
163 enrolled
GARDASIL Reexamination Study (V501-059)
Completed
3,605 enrolled 6 charts
Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients
Phase 4 Completed
197 enrolled
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
Phase 4 Completed
7 enrolled
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
Phase 2 Completed
200 enrolled